We claim:

1. A tumor-associated antigen (TAA) presentation inducer construct comprising

a) at least one innate stimulatory receptor (ISR)-binding construct that binds to an ISR expressed on an antigen-presenting cell (APC), and

b) at least one TAA-binding construct that binds directly to a first TAA that is physically associated with tumor cell-derived material (TCDM) comprising one or more other TAAs,

wherein said ISR-binding construct and said TAA-binding construct are linked to each other, and

wherein the TAA presentation inducer construct induces a polyclonal T cell response to the one or more other TAAs.

2. The TAA presentation inducer construct according to claim 1, wherein the ISR is a C-type lectin receptor, a member of the tumor necrosis factor receptor family, or a lipoprotein receptor.

3. The TAA presentation inducer construct according claim 2, wherein the innate stimulatory receptor is a C-type lectin receptor.

4. The TAA presentation inducer construct according to claim 3, wherein the C-type lectin receptor is dectin-1, dectin-2, DEC205, Mincle, or DC-SIGN.

5. The TAA presentation inducer construct according to claim 2, wherein the innate stimulatory receptor is CD40 or LRP-1.

6. The TAA presentation inducer construct according to any one of claims 1 to 5, wherein the first TAA is highly expressed in cancer cells, is a low immunoscore TAA, or is an oncofetal antigen.

7. The TAA presentation inducer construct according to any one of claims 1 to 5, wherein the first TAA is HER2, ROR1, or PSMA.

8. The TAA presentation inducer construct according to any one of claims 1 to 7, wherein the at least one ISR-binding construct and/or the at least one TAA-binding construct is a peptide, or a polypeptide.

9. The TAA presentation inducer construct according to claim 8, wherein the at least one ISR-binding construct is an antigen-binding domain and/or the at least one TAA-binding construct is an antigen-binding domain.

10. The TAA presentation inducer according to any one of claims 1 to 9, wherein the TAA presentation inducer comprises two or more ISR-binding constructs.

11. The TAA presentation inducer according to claim 10, wherein the two or more ISR-binding constructs bind to two or more different ISRs.

12. The TAA presentation inducer according to any one of claims 1 to 9, wherein the TAA presentation inducer comprises two or more TAA-binding constructs.

13. The TAA presentation inducer according to claim 12, wherein the two or more TAA-binding constructs bind to different antigens.

14. The TAA presentation inducer according to any one of claims 1 to 13, wherein the at least one ISR-binding construct and the at least one TAA-binding construct are linked directly to each other.

15. The TAA presentation inducer according to any one of claims 1 to 13, wherein the at least one ISR-binding construct and the at least one TAA-binding construct are linked to each other with a linker.

16. The TAA presentation inducer according to claim 15, wherein the linker is an Fc.

17. The TAA presentation inducer according to any one of claims 1 to 16, wherein the TAA presentation inducer is a bispecific antibody that binds to an ISR and to a TAA.

18. The TAA presentation inducer construct according to any one of claims 1 to 17, wherein the TAA presentation inducer construct is conjugated to a drug.

19. A pharmaceutical composition comprising the TAA presentation inducer construct according to any one of claims 1 to 18.

20. One or more nucleic acids encoding the TAA presentation inducer construct according to any one of claims 1 to 18.

21. One or more vectors comprising the one or more nucleic acids according to claim 20.

22. A host cell comprising the one or more nucleic acids according to claim 20, or the one or more vectors according to claim 21.

23. A method of making the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims 1 to 18, comprising:

a) expressing the one or more nucleic acids of claim 20 or the one or more vectors of claim 21 in a cell.

24. A method of treating cancer comprising administering the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims 1 to 18 to a subject in need thereof.

25. A method of inducing major histocompatibility complex (MHC) presentation of peptides from two or more tumor-associated antigens (TAAs) by a single innate stimulatory receptor-expressing cell simultaneously in a subject, comprising administering to the subject the TAA presentation inducer construct according to any one of claims 1 to 18.

26. A method of inducing innate stimulatory receptor-expressing cell activation in a subject, comprising administering to the subject, the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims 1 to 18.

27. A method of inducing a polyclonal T cell response in a subject, comprising administering to the subject the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims 1 to 18.

28. A method of expanding, activating, or differentiating T cells specific for two or more tumor-associated antigens (TAAs) simultaneously, comprising:

a) obtaining T cells and innate stimulatory receptor (ISR)-expressing cells from a subject; and

b) culturing the T cells and the ISR-expressing cells with the TAA presentation inducer construct according to any one of claims 1 to 18 in the presence of tumor cell-derived material (TCDM), to produce expanded, activated or differentiated T cells.

29. The method according to claim 28, wherein the TCDM is from an autologous tissue sample, or from a tumor cell line.

30. A method of treating cancer in a subject, comprising administering to the subject the expanded, activated or differentiated T cells prepared according to the method of claim 28 or 29.

31. A method of identifying tumor-associated antigens in tumor cell-derived material (TCDM) comprising

a) isolating T cells and enriched innate stimulatory receptor (ISR)-expressing cells from a subject;

b) culturing the ISR-expressing cells and the T cells with the TAA presentation inducer construct according to